LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.

医学 富维斯特朗 耐受性 转移性乳腺癌 内科学 临床终点 乳腺癌 肿瘤科 安慰剂 癌症 阿那曲唑 随机对照试验 不利影响 三苯氧胺 病理 替代医学
作者
Bo Xu,Qingyuan Zhang,Yang Luo,Zhongsheng Tong,Tao Sun,Changping Shan,Xinlan Liu,Yali Yao,Bing Zhao,Shusen Wang,Xiaohua Zeng,Changlu Hu,Xi Yan,Xiaojia Wang,Hong-Ti Jia,Zhendong Chen,Fuming Qiu,Xinhong Wu,Deyong Zhang,Tong Li
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 1017-1017 被引量:1
标识
DOI:10.1200/jco.2023.41.16_suppl.1017
摘要

1017 Background: Lerociclib (GB491), a novel oral CDK4/6 inhibitor with continuously daily dosing, which has demonstrated anti-tumor response and a differentiated safety & tolerability profile in previous clinical trials. The LEONARDA-1 study assessed the efficacy of lerociclib and fulvestrant in endocrine-resistant advanced BC. Methods: This is a randomized, double-blind, placebo-controlled phase III study assessing lerociclib in combination with fulvestrant in pre/peri-menopausal or postmenopausal, HR+, HER2- locally advanced or metastatic BC patients (pts) who had relapsed or progressed on prior endocrine therapy (ET). Eligible patients were allowed one prior line of chemotherapy for metastatic disease. Pre-/peri-menopausal pts also received goserelin. Pts were randomized 1:1 to receive lerociclib (150mg po bid, d1-28, q4w) or placebo (P) plus fulvestrant (F). The primary endpoint was investigator-assessed progression-free survival (PFS) based on RECIST v1.1. Secondary endpoints included PFS (assessed by BICR), overall survival (OS), response assessment, safety and tolerability, pharmacokinetic (PK) profile. Results: By December 2 nd 2022 as data cut-off date, 275 pts were randomized, 137 to receive lerociclib + F and 138 to P + F. Median follow-up time was 7.36 months (range, 0.03-11.93+) for lerociclib + F vs 7.33 months (range, 0.03-11.27) for P + F. Baseline characteristics were well balanced (The median age was 54 years and 53.5 years, 41.6%% and 44.9% were Pre/peri-menopausal, 64.2% and 62.3% had visceral disease, 24.8% and 26.1% were primary resistant to prior ET, 28.5% and 29.0% received one line of chemotherapy for metastatic disease, respectively). At the time of cut-off date, 125 PFS events were observed with a median PFS of 11.07 months for lerociclib + F and 5.49 months for P + F (HR: 0.458; 95% CI: 0.317, 0.661, P< 0.001 by log-rank test). In patients with measurable disease (n=240, 87.3%), the ORR was significantly higher in lerociclib + F 26.9% (2.5% complete response [CR]) vs 9.9% (0% CR) for P + F. Consistent benefit from lerociclib was seen in pre/peri-menopausal and postmenopausal subjects. The most common adverse events (AEs) for lerociclib + F versus P + F were neutropenia (90.5% vs. 4.3%), leucopenia (86.9% vs. 6.5%), anemia (34.3% vs. 10.1%), thrombocytopenia (19.7% vs. 3.6%), and diarrhea (19.7% vs. 3.6%). Grade 3 or 4 neutropenia was reported in 46.7% pts on lerociclib + F (G3: 41.6%, G4: 5.1%) vs 0% pts on P + F. There was no case of ≥Grade3 diarrhea reported. The discontinuation rate due to AEs was 0.7% on lerociclib + F and 0% on P + F. Serious AEs were reported for 5.8% and 8.0%, respectively. Conclusions: Lerociclib at 150mg twice daily plus fulvestrant significantly improved PFS and ORR and demonstrated a favorable tolerable safety profile in pts with HR+ / HER2- endocrine-resistant advanced BC. Clinical trial information: NCT05054751 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
owldan完成签到 ,获得积分10
2秒前
一直向前完成签到,获得积分10
2秒前
舒服的映安完成签到 ,获得积分10
2秒前
lmh011115发布了新的文献求助10
3秒前
4秒前
一直向前发布了新的文献求助10
4秒前
End完成签到 ,获得积分10
5秒前
沉静的红酒完成签到,获得积分10
6秒前
yzxzdm完成签到 ,获得积分10
6秒前
Yara.H完成签到 ,获得积分10
6秒前
Meng完成签到,获得积分10
7秒前
9秒前
量子星尘发布了新的文献求助10
11秒前
包容追命发布了新的文献求助10
13秒前
13秒前
梦鱼完成签到,获得积分10
14秒前
小林不熬夜完成签到,获得积分10
14秒前
玛卡巴卡完成签到,获得积分10
15秒前
希尔伯特发布了新的文献求助10
17秒前
Jasper应助dailyyang采纳,获得10
17秒前
冬凌草完成签到 ,获得积分10
17秒前
阿若完成签到,获得积分10
17秒前
英姑应助单纯冰棍采纳,获得10
17秒前
高高从霜完成签到 ,获得积分10
18秒前
lmh011115完成签到,获得积分10
18秒前
包容追命完成签到,获得积分20
19秒前
zhenya完成签到,获得积分10
20秒前
xiang929完成签到 ,获得积分10
22秒前
小文子完成签到,获得积分10
22秒前
Mae完成签到 ,获得积分10
23秒前
23秒前
24秒前
24秒前
X欣完成签到,获得积分10
24秒前
lelele完成签到,获得积分10
24秒前
可爱的函函应助luxi0714采纳,获得10
26秒前
月儿完成签到 ,获得积分10
26秒前
小曾应助景清采纳,获得10
27秒前
27秒前
大力的忆霜完成签到,获得积分10
27秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048